Quick Answer
Seres Therapeutics, Inc. reported Diluted EPS of $0.64 per share for fiscal year 2025.
Seres Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $0.64 | — |
| 2024 | $0.00 | +100.0% |
| 2023 | -$17.77 | -669.3% |
| 2022 | -$2.31 | -220.8% |
| 2021 | -$0.72 | +35.7% |
| 2020 | -$1.12 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.94 | -91.9% | +141.4% |
| June 30, 2025 | -$2.27 | +47.7% | -160.5% |
| March 31, 2025 | $3.75 | +168.3% | -67.8% |
| September 30, 2024 | $11.63 | +3243.2% | +368.0% |
| June 30, 2024 | -$4.34 | -1305.6% | +20.9% |
| March 31, 2024 | -$5.49 | -863.2% | -1383.8% |
| September 30, 2023 | -$0.37 | +24.5% | -202.8% |
| June 30, 2023 | $0.36 | +151.4% | +163.2% |
- Over the 2020–2025 period, Seres Therapeutics, Inc.’s diluted eps has grown by 157.1% (from $1.12 per share (loss) to $0.64 per share).
- The most recent figure is from Seres Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: